Overview: The Union Budget 2026-27 introduced the Biopharma SHAKTI scheme with a ₹10,000 crore outlay to transform India into a global manufacturing hub for biologics and biosimilars. This initiative aligns with the budget’s vision to sustain economic growth while scaling up manufacturing in critical, frontier sectors.
Key Points:
- The Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology & Innovation) scheme was announced with a ₹10,000 crore budget over 5 years.
- It aims to pivot the Indian pharmaceutical industry from low-cost generic drugs to high-value biologics and biosimilar manufacturing.
- The budget mandates the establishment of three new national institutes and the upgradation of seven existing ones for advanced pharma research.
- This move addresses the global supply chain realignments, ensuring long-term health security and import substitution for critical medicines.
- It directly supports the “Yuva Shakti” theme of the budget by creating high-skilled employment and industry-led research centers.
Source Link: India Budget Official Portal
- MCQ: Consider the following statements regarding the ‘Biopharma SHAKTI’ scheme introduced in the Union Budget 2026-27:
- It exclusively focuses on the mass production of traditional Ayurvedic medicines.
- It aims to build a domestic ecosystem for the production of biologics and biosimilars.
Which of the statements given above is/are correct?
(A) 1 only
(B) 2 only
(C) Both 1 and 2
(D) Neither 1 nor 2
